JP2024539150A - 眼の状態を治療、予防、阻害、改善、又はその発症を遅延させるためのペプチド模倣物を含む方法及び組成物 - Google Patents

眼の状態を治療、予防、阻害、改善、又はその発症を遅延させるためのペプチド模倣物を含む方法及び組成物 Download PDF

Info

Publication number
JP2024539150A
JP2024539150A JP2024523648A JP2024523648A JP2024539150A JP 2024539150 A JP2024539150 A JP 2024539150A JP 2024523648 A JP2024523648 A JP 2024523648A JP 2024523648 A JP2024523648 A JP 2024523648A JP 2024539150 A JP2024539150 A JP 2024539150A
Authority
JP
Japan
Prior art keywords
formula
peptidomimetic
amino
subject
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539150A5 (https=
Inventor
デニス キーフ
マーティン レドモン
ブライアン ホッチキス
アンソニー アブルスカト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/045908 external-priority patent/WO2023069255A1/en
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of JP2024539150A publication Critical patent/JP2024539150A/ja
Publication of JP2024539150A5 publication Critical patent/JP2024539150A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024523648A 2021-10-20 2022-10-19 眼の状態を治療、予防、阻害、改善、又はその発症を遅延させるためのペプチド模倣物を含む方法及び組成物 Pending JP2024539150A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163257738P 2021-10-20 2021-10-20
US63/257,738 2021-10-20
US202263331412P 2022-04-15 2022-04-15
US63/331,412 2022-04-15
PCT/US2022/045908 WO2023069255A1 (en) 2021-10-20 2022-10-06 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
USPCT/US2022/045908 2022-10-06
PCT/US2022/047172 WO2023069549A1 (en) 2021-10-20 2022-10-19 Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Publications (2)

Publication Number Publication Date
JP2024539150A true JP2024539150A (ja) 2024-10-28
JP2024539150A5 JP2024539150A5 (https=) 2025-10-27

Family

ID=84329344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523648A Pending JP2024539150A (ja) 2021-10-20 2022-10-19 眼の状態を治療、予防、阻害、改善、又はその発症を遅延させるためのペプチド模倣物を含む方法及び組成物

Country Status (8)

Country Link
US (1) US20230405080A1 (https=)
EP (1) EP4419123A1 (https=)
JP (1) JP2024539150A (https=)
KR (1) KR20240108412A (https=)
AU (1) AU2022370358A1 (https=)
CA (1) CA3234071A1 (https=)
IL (1) IL312199A (https=)
WO (1) WO2023069549A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719404A2 (en) * 2023-05-25 2026-04-08 Stealth BioTherapeutics Inc. Methods for addressing injection site reactions associated with the administration of bevemipretide
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
US20260048096A1 (en) * 2024-08-19 2026-02-19 Stealth Biotherapeutics Inc. Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
AU2015264908B2 (en) * 2008-05-09 2017-06-29 Pari Pharma Gmbh Nebuliser for Ventilation Machines and a Ventilation Machine Comprising such a Nebuliser
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CN115919996A (zh) * 2015-05-01 2023-04-07 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
ES2942631T3 (es) * 2017-12-15 2023-06-05 Stealth Biotherapeutics Inc Péptidos dirigidos a mitocondrias
CN112165954A (zh) * 2018-03-23 2021-01-01 阿奇生物外科有限公司 用于治疗眼病的sap和拟肽
AU2020316449B2 (en) * 2019-07-24 2026-02-05 Stealth Biotherapeutics Inc. The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2022370358A1 (en) 2024-05-02
IL312199A (en) 2024-06-01
WO2023069549A1 (en) 2023-04-27
KR20240108412A (ko) 2024-07-09
US20230405080A1 (en) 2023-12-21
EP4419123A1 (en) 2024-08-28
CA3234071A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US20230405080A1 (en) Methods and compositions for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
JP7638265B2 (ja) 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
US20240024408A1 (en) Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20210401925A1 (en) Methods and compositions for preventing or treating dominant optic atrophy
WO2023069255A1 (en) Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
KR20260042546A (ko) 리 증후군의 치료 및 예방과 관련된 방법, 조성물 및 용도
JP4566130B2 (ja) 角膜知覚回復剤
CN118434434A (zh) 用于治疗、预防、抑制、改善眼科病状或延缓其发作的方法和包括肽模拟物的组合物
US20250090504A1 (en) Small molecule peptidomimetic for the treatment of tauopathies
US20250319073A1 (en) Compositions and methods for the treatment of huntington’s disease and htt proteinopathies
US20250025526A1 (en) Combination therapy for the treatment of friedreich's ataxia
WO2026043737A1 (en) Methods and compositions for preserving the retinal outer nuclear layer (onl), photoreceptors, and retinal thickness
WO2022162030A1 (en) Peptides for inhibiting angiogenesis
HK40073767B (en) The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis
HK40073767A (en) The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017